ACT Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

ACT Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$758K	Buy	+28,100	New	+$771K	0.5%	32

Other funds holding MLYS

Andera Partners Paris $206M AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Eleva Capital Paris, France $343M AUM

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

ACT Capital Management's MLYS Position: Q2 2026 in Review

ACT Capital Management opened a new position in Mineralys Therapeutics (MLYS) in Q2 2026: 28,100 shares worth $758K. The stake represents 0.5% of the portfolio and ranks #32 among its holdings.

29 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

ACT Capital Management held 28,100 shares of Mineralys Therapeutics worth $758K as of Q2 2026.
Mineralys Therapeutics was a new ACT Capital Management position in Q2 2026.
Mineralys Therapeutics made up 0.5% of ACT Capital Management's portfolio in Q2 2026, its #32 holding.
29 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.